Cue Biopharma, Inc. (CUE)
28.74
+0.74
(+2.64%)
USD |
NASDAQ |
Sep 11, 16:00
28.83
+0.09
(+0.31%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 150.29M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 25.11% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 3.472 |
| Price to Book Value | 65.06 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 3.813 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.01% |
Profile
| Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA. |
| URL | http://www.cuebiopharma.com |
| Investor Relations URL | https://www.cuebiopharma.com/investors-media/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA. |
| URL | http://www.cuebiopharma.com |
| Investor Relations URL | https://www.cuebiopharma.com/investors-media/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |